Study guide

7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

Key Takeaways Explain This Topic AI

Minimum Alveolar Concentration (MAC) is the alveolar concentration at 1 atm preventing movement in 50% of subjects in response to surgical skin incision; standard 1 MAC values in 100% O 2 O_2 O 2 ​ are halothane 0.75%, isoflurane 1.15%, sevoflurane 2.0%, desflurane 6.0%, and nitrous oxide 104%.

MAC decreases by approximately 6% per decade of life after 40, is reduced by hypothermia, acute alcohol, opioids, pregnancy, and α 2 \alpha_2 α 2 ​ -agonists, is increased by hyperthermia, hypernatremia, and chronic alcohol abuse, but is unaffected by gender, duration of anaesthesia, hypertension, or thyroid status per se.

Volatile anaesthetics produce dose-dependent myocardial depression, blunt baroreceptor reflexes, depress hypercapnic and hypoxic ventilatory responses, and uncouple cerebral blood flow (CBF) from cerebral metabolic rate ( C M R O 2 CMRO_2 CMR O 2 ​ ) at concentrations > 1 MAC >1\text{ MAC} > 1 MAC , potentially increasing intracranial pressure.

Specific toxicities include Compound A nephrotoxicity from sevoflurane degradation by strong bases in desiccated absorbents, carbon monoxide generation (desflurane > isoflurane >> sevoflurane), immune-mediated halothane hepatitis via trifluoroacetylated protein neoantigens, and malignant hyperthermia triggered via RYR1 mutations treated urgently with dantrolene.

Last updated: October 2026

7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

Inhalational anaesthetics exert widespread systemic effects across every major organ system while inducing general anaesthesia. Establishing clinical depth requires an objective pharmacological standard: the Minimum Alveolar Concentration (MAC). Alongside their therapeutic actions, volatile agents carry distinct organ toxicities and trigger lethal pharmacogenetic crises such as Malignant Hyperthermia.

1. MAC Concept, Mathematical Definitions, and Clinical Subtypes

Introduced by Eger and colleagues, Minimum Alveolar Concentration (MAC) is defined as the steady-state end-tidal alveolar concentration of an inhalational agent at 1 atmosphere (101.3 kPa / 760 mmHg) that prevents purposeful skeletal muscle movement in 50% of subjects in response to a standard supramaximal noxious stimulus (traditionally surgical skin incision).

MAC = Median Effective Dose ( E D 50 ) for immobility at 1 atmosphere \text{MAC} = \text{Median Effective Dose } (ED_{50}) \text{ for immobility at } 1\text{ atmosphere} MAC = Median Effective Dose ( E D 50 ​ ) for immobility at 1 atmosphere

End-tidal alveolar partial pressure ( P A P_A P A ​ ) is measured because at steady state, alveolar gas is in equilibrium with arterial blood and central nervous system tissue. Crucially, the immobility reflected by MAC is mediated primarily by action on ventral horn motor neurons and interneurons in the spinal cord , rather than cerebral cortex depression.

Volatile Agent 1 MAC Value (in 100% O 2 \text{O}_2 O 2 ​ , 40-year-old adult) 1 MAC Equivalent Partial Pressure (kPa / mmHg)

  • Halothane 0.75% 0.76 kPa / 5.7 mmHg
  • Isoflurane 1.15% 1.17 kPa / 8.7 mmHg
  • Sevoflurane 2.0% (range 1.8 - 2.1%) 2.03 kPa / 15.2 mmHg
  • Desflurane 6.0% (range 6.0 - 6.6%) 6.08 kPa / 45.6 mmHg
  • Nitrous Oxide ( N 2 O N_2O N 2 ​ O ) 104% 105.4 kPa / 790 mmHg (achievable only in hyperbaric chamber)
  • Xenon 63% - 71% 64.0 - 72.0 kPa / 480 - 540 mmHg
  • Clinical MAC Subtypes

MAC awake \text{MAC}_{\text{awake}} MAC awake ​ (~0.3 to 0.4 MAC): The alveolar concentration at which 50% of patients open their eyes or execute appropriate voluntary responses to verbal command upon emergence. Corresponds to loss of recall and suppression of consciousness (amnesia).

MAC BAR \text{MAC}_{\text{BAR}} MAC BAR ​ (~1.5 MAC): The alveolar concentration required to Blunt Autonomic Response (sympathetic surge, tachycardia, hypertension, pupillary dilation, and diaphoresis) to noxious surgical incision. Can be reduced dramatically to ~1.0 MAC with concurrent opioid administration.

MAC 95 \text{MAC}_{95} MAC 95 ​ (~1.3 MAC): The alveolar concentration preventing purposeful movement in 95% of patients ( 1.3 × 1 MAC 1.3 \times 1\text{ MAC} 1.3 × 1 MAC ). Typically targeted as the baseline clinical depth for surgical incision.

MAC intubation \text{MAC}_{\text{intubation}} MAC intubation ​ (~1.3 to 1.5 MAC): The alveolar concentration preventing movement and coughing during endotracheal intubation in the absence of neuromuscular blocking drugs.

Additivity of MAC: MAC fractions are strictly additive. For instance, administering 0.5 MAC of nitrous oxide (52%) alongside 0.5 MAC of sevoflurane (1.0%) delivers 1.0 MAC of total anaesthetic depth.

  • 2. Factors Governing Minimum Alveolar Concentration FACTORS MODULATING MAC
  • |
  • +-----------------------+-----------------------+
  • | |
  • Factors Decreasing MAC Factors Increasing MAC
  • Increasing age (~6%/decade) - Hyperthermia (>38.5°C)
  • Hypothermia (~5%/°C) - Hypernatremia
  • Acute alcohol ingestion - Chronic alcohol abuse
  • Sedatives, Opioids, Ketamine - Chronic amphetamine / cocaine abuse
  • Alpha-2 agonists (clonidine, dex) - Infant age (peak 1-6 months)
  • Pregnancy / postpartum - Acute amphetamine use
  • Hypoxia (PaO2 < 38 mmHg) - Red hair phenotype (MC1R mutation)
  • Hypotension (MAP < 40 mmHg)
  • Hyponatremia, Lithium, Lidocaine
  • FACTORS WITH NO EFFECT ON MAC: Gender, Duration of anaesthesia,
  • Arterial PaCO2 (20-95 mmHg), Hypertension, Thyroid status per se
  • Factors Decreasing MAC

Age: MAC peaks in infants aged 1 to 6 months and declines progressively thereafter. After age 40, MAC decreases by approximately 6% per decade of life due to progressive reductions in neuronal density, neurotransmitter synthesis, and cerebral metabolic rate.

Hypothermia: MAC decreases by ~5% per 1°C fall in core body temperature , reflecting decreased neuronal enzyme activity and enhanced gas solubility in tissues.

Acute Intoxication: Acute alcohol intake acts synergistically with G A B A A GABA_A G A B A A ​ transmission, markedly lowering MAC.

Adjuvant Drugs: Intravenous sedatives (propofol, benzodiazepines, barbiturates), opioids (which plateau at ~60-80% MAC reduction), and intravenous lidocaine.

α 2 \alpha_2 α 2 ​ -Adrenoceptor Agonists: Clonidine and dexmedetomidine produce dramatic, dose-dependent MAC reductions (up to 60-80%) via presynaptic G i G_i G i ​ -mediated inhibition of locus coeruleus noradrenergic firing.

Pregnancy: Elevated circulating progesterone and endorphin levels reduce MAC by ~30-40% starting in the first trimester, returning to baseline within 24-72 hours postpartum.

Severe Physiological Derangements: Extreme arterial hypoxemia ( P a O 2 < 38 mmHg / 5 kPa PaO_2 < 38\text{ mmHg} / 5\text{ kPa} P a O 2 ​ < 38 mmHg /5 kPa ), severe arterial hypotension ( M A P < 40 − 50 mmHg MAP < 40-50\text{ mmHg} M A P < 40 − 50 mmHg ), hyponatremia (reduced CSF osmolarity), and metabolic acidosis.

Factors Increasing MAC

Hyperthermia: Elevated core temperature ( > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C ) increases MAC by ~5% per 1°C.

Hypernatremia: Elevated serum and CSF sodium concentrations increase central neuronal excitability.

Age: Highest MAC requirements occur in infants aged 1 to 6 months (sevoflurane 1 MAC is ~3.2-3.3% in infants vs 2.0% in 40-year-olds; neonates < 30 <30 < 30 days have slightly lower MAC than older infants).

Chronic Substance Abuse: Chronic alcoholism and chronic amphetamine or cocaine abuse upregulate central excitatory pathways and induce tolerance, shifting MAC higher.

Acute Sympathetic Stimulants: Acute amphetamine ingestion surges synaptic monoamine concentrations, raising MAC.

Red Hair Phenotype: Mutations in the melanocortin-1 receptor ( MC1R ) gene linked to pheomelanin production correlate with an ~19% increase in volatile anaesthetic requirement (desflurane).

Factors Having NO Direct Effect on MAC

Gender / Biological Sex: MAC values do not differ significantly between males and females.

Duration of Anaesthesia: Anaesthetic requirement does not decrease or increase with prolonged exposure.

Arterial P a C O 2 PaCO_2 P a C O 2 ​ (20 - 95 mmHg): Within this range, P a C O 2 PaCO_2 P a C O 2 ​ does not change MAC. Only extreme hypercapnia ( P a C O 2 > 95 − 100 mmHg PaCO_2 > 95-100\text{ mmHg} P a C O 2 ​ > 95 − 100 mmHg ) produces C O 2 CO_2 C O 2 ​ narcosis, decreasing MAC.

Hypertension: Baseline systemic arterial hypertension has no impact on MAC.

Thyroid Status per se: Neither hyperthyroidism nor hypothyroidism directly alters neuronal MAC requirements. While hyperthyroidism increases cardiac output (which slows F A / F I F_A/F_I F A ​ / F I ​ wash-in), intrinsic cerebral tissue sensitivity remains completely unaltered.

3. Organ System Effects: Cardiovascular and Hemodynamic Profiles Cardiovascular Profiles of Modern Volatile Agents at 1 MAC:

  • Parameter Sevoflurane Isoflurane Desflurane Halothane
  • -------------------------------------------------------------------------------
  • Contractility Decreased (++) Decreased (++) Decreased (++) Decreased (+++)
  • SVR Decreased (++) Decreased (+++) Decreased (+++) Unchanged
  • Mean Art Pressure Decreased (++) Decreased (++) Decreased (++) Decreased (+++)
  • Heart Rate Unchanged / mild Moderate rise Surges on rapid Decreased /
  • rise at >1 MAC at >1 MAC concentration ^ Bradycardia
  • Coronary Steal Negligible Arteriolar dil. Negligible None
  • (theoretical)
  • Myocardial Depression and Vascular Resistance

All volatile anaesthetics produce dose-dependent myocardial depression by inhibiting sarcolemmal L-type calcium channels, attenuating calcium-induced calcium release from the sarcoplasmic reticulum, and decreasing myofibrillar calcium sensitivity:

Isoflurane and Desflurane: Primarily lower mean arterial pressure ( M A P MAP M A P ) by causing direct systemic arteriolar vasodilation, resulting in marked reductions in Systemic Vascular Resistance (SVR) .

Sevoflurane: Causes modest SVR reduction and maintains cardiac output better than isoflurane at 1 MAC.

Halothane: Leaves SVR largely unchanged but directly depresses myocardial contractility and stroke volume, dropping cardiac output by 30-50% at 1-1.5 MAC.

Baroreceptor Reflex and Desflurane Autonomic Surge

Volatile agents blunt baroreceptor reflex sensitivity in a dose-dependent fashion, attenuating compensatory tachycardia during hypotension.

Desflurane Tachycardia Surge: Rapid upward titration of desflurane concentration ( > 1 MAC >1\text{ MAC} > 1 MAC increment, e.g. stepping from 3% to 7%) stimulates sensory irritant receptors in the tracheobronchial tree, triggering reflex central sympathetic stimulation with transient surges in heart rate, arterial hypertension, and circulating norepinephrine. This surge can be mitigated by prior administration of intravenous fentanyl, esmolol, or clonidine.

The Coronary Steal Controversy

Isoflurane is a potent coronary arteriolar vasodilator, preferentially relaxing small resistance microvessels ( < 100 μ m <100\ \mu\text{m} < 100 μ m ). In theory, if a patient has a critical coronary stenosis with collateral-dependent myocardium where arterioles are already maximally dilated, dilating vessels in non-stenotic zones could divert blood away from the ischemic territory (the "coronary steal" phenomenon ). However, extensive clinical trials confirm that coronary steal is virtually absent in clinical practice provided that coronary perfusion pressure is maintained ( M A P > 65 − 70 mmHg MAP > 65-70\text{ mmHg} M A P > 65 − 70 mmHg ).

  • 4. Respiratory Mechanics and Airway Irritation
  • Ventilatory Pattern and Minute Ventilation

Volatile agents depress alveolar ventilation in a dose-dependent manner by direct actions on the medullary respiratory rhythm generator:

Tidal Volume ( V T V_T V T ​ ): Markedly reduced across all volatile agents.

Respiratory Rate ( R R RR RR ): Compensatory increase (rapid, shallow breathing pattern), but insufficient to prevent a net drop in minute ventilation ( V ˙ E \dot{V}_E V ˙ E ​ ).

Arterial Carbon Dioxide ( P a C O 2 PaCO_2 P a C O 2 ​ ): Resting P a C O 2 PaCO_2 P a C O 2 ​ rises progressively with increasing anaesthetic depth (apneic threshold shifts rightward).

Chemosensory Ventilatory Drives

Hypercapnic Ventilatory Drive: The ventilatory response curve to elevated C O 2 CO_2 C O 2 ​ is shifted to the right and its slope is markedly flattened. At 1.5-2.0 MAC, the hypercapnic drive is abolished.

Hypoxic Ventilatory Drive: Peripheral chemoreceptors in the carotid bodies are exceptionally sensitive to inhalational agents. Sub-anaesthetic concentrations ( 0.1 MAC ) suppress 50-70% of the hypoxic ventilatory response; 1.0 MAC completely extinguishes it . This leaves postoperative patients vulnerable to undetected hypoxemia in the post-anaesthesia care unit (PACU).

Bronchodilation vs Airway Pungency

Bronchodilation: Volatile agents are potent direct bronchodilators, reversing acetylcholine- and histamine-induced bronchospasm by lowering intracellular calcium in bronchial smooth muscle (sevoflurane ≥ \ge ≥ isoflurane > desflurane). Indicated for life-threatening refractory status asthmaticus.

Airway Pungency: Sevoflurane has a sweet, non-pungent odor and does not irritate airway mucosa, making it the agent of choice for inhalational mask induction . In contrast, desflurane and isoflurane are pungent and irritating , triggering salivation, coughing, breath-holding, and severe laryngospasm if introduced without prior intravenous induction.

5. Central Nervous System Dynamics: Metabolism, Flow, and Epileptogenesis CNS Uncoupling Effect (>1 MAC):

  • Physiological State: CMRO2 and CBF are coupled
  • CMRO2 Decreases ====> CBF Decreases (Metabolic vasoconstriction)
  • Volatile Anaesthesia (>1 MAC): UNCOUPLING OCCURS
  • CMRO2 Decreases ====> Neuronal depression (Isoelectric EEG at 1.5-2.0 MAC)
  • Direct Vasodilation ===> CBF INCREASES ====> ICP RISES
  • Management: Mild hyperventilation (PaCO2 30-35 mmHg) restores vasoconstriction
  • Cerebral Metabolic Rate ( C M R O 2 CMRO_2 CMR O 2 ​ ) and Cerebral Blood Flow (CBF)

Volatile agents decrease cerebral metabolic rate for oxygen ( C M R O 2 CMRO_2 CMR O 2 ​ ) in a dose-dependent manner up to ~50% reduction, at which point an isoelectric (flatline) EEG is achieved (burst suppression occurs at 1.5-2.0 MAC).

Direct intrinsic vascular action: Volatile agents are direct cerebral arteriolar vasodilators.

The Uncoupling Phenomenon: At concentrations < 1 MAC <1\text{ MAC} < 1 MAC , metabolic suppression predominates, keeping CBF stable or reduced. At concentrations > 1 MAC >1\text{ MAC} > 1 MAC , direct intrinsic cerebral vasodilation overrides metabolic vasoconstriction, causing uncoupling : CBF increases despite a falling C M R O 2 CMRO_2 CMR O 2 ​ . The rise in CBF increases intracranial blood volume and intracranial pressure (ICP), especially in patients with space-occupying intracranial lesions.

Mitigation: Mild hyperventilation to maintain P a C O 2 PaCO_2 P a C O 2 ​ around 30-35 mmHg (4.0-4.7 kPa) preserves responsive cerebral vasoconstriction and blunts the rise in ICP.

Epileptogenic Potential of Sevoflurane

At high concentrations ( > 1.5 MAC >1.5\text{ MAC} > 1.5 MAC ), particularly when combined with hyperventilation (hypocapnia) during paediatric mask induction, sevoflurane can induce epileptiform electroencephalographic activity, including spike-and-wave patterns, burst suppression, and clinical myoclonic seizure-like motor activity. Desflurane and isoflurane do not possess epileptogenic potential; isoflurane is a potent anticonvulsant.

  • 6. Specific Toxicities, Degradation, and Emergencies
  • Fluoride-Induced Nephrotoxicity

Methoxyflurane: Extensively biotransformed (~50%) by hepatic CYP2E1, releasing large amounts of free inorganic fluoride ion ( F − F^- F − ). Serum F − F^- F − concentrations exceeding 50 μ mol/L 50\ \mu\text{mol/L} 50 μ mol/L caused vasopressin-resistant high-output polyuric renal failure.

Sevoflurane: Undergoes ~2-5% hepatic metabolism by CYP2E1, yielding fluoride ions and hexafluoroisopropanol (HFIP). Although serum F − F^- F − can transiently exceed 50 μ mol/L 50\ \mu\text{mol/L} 50 μ mol/L after prolonged operations, sevoflurane does not cause nephrogenic diabetes insipidus or renal failure . Sevoflurane is metabolized almost exclusively in the liver rather than intrarenally, and inorganic fluoride is cleared rapidly without accumulating in renal medullary architecture.

Carbon Dioxide Absorbent Degradation: Compound A and Carbon Monoxide

Phenomenon Causative Agent(s) Mechanism & Catalysts Clinical Manifestations & Safety Measures

Compound A Sevoflurane Degradation of sevoflurane by strong base catalysts (potassium hydroxide KOH \text{KOH} KOH and sodium hydroxide NaOH \text{NaOH} NaOH ) in carbon dioxide absorbents (soda lime, Baralyme). Catalyzed by: desiccated absorbent, warm absorbent temperature, low fresh gas flow, high sevoflurane concentrations. Nephrotoxic and hepatotoxic in laboratory rats (proximal tubular necrosis). Prevented by maintaining fresh gas flows ≥ 1 − 2 L/min \ge 1-2\text{ L/min} ≥ 1 − 2 L/min or using modern calcium hydroxide absorbents devoid of KOH / NaOH \text{KOH}/\text{NaOH} KOH / NaOH .

Carbon Monoxide (CO) Desflurane > Isoflurane ≫ \gg ≫ Sevoflurane Volatile agents passing through completely dry (desiccated) absorbents containing strong bases ( KOH > NaOH \text{KOH} > \text{NaOH} KOH > NaOH ) are degraded into toxic carbon monoxide. Produces acute, occult carboxyhemoglobinemia . Classically presents on Monday mornings when fresh gas flows were left running over the weekend, desiccating the canisters. Modern pulse oximeters overestimate SpO 2 \text{SpO}_2 SpO 2 ​ during CO poisoning.

Halothane Hepatitis

Halothane undergoes ~20% hepatic biotransformation via CYP2E1, producing a reactive acyl halide intermediate: trifluoroacetyl (TFA) chloride . TFA chloride covalently binds to hepatic microsomal proteins, forming trifluoroacetylated neoantigens. In genetically susceptible individuals, these neoantigens provoke an autoimmune, antibody-mediated cytotoxic T-cell response against hepatocytes upon re-exposure:

Severe form presents 3-10 days post-exposure with fever, anorexia, jaundice, marked transaminitis ( A S T / A L T > 10,000 U/L AST/ALT > 10{,}000\text{ U/L} A ST / A L T > 10 , 000 U/L ), hepatic encephalopathy, and high mortality (~50-80%).

Risk factors: Repeated exposures (especially within 3 months), female sex, obesity, and middle age.

Modern fluorinated agents: Desflurane is metabolized ~0.02% to TFA and isoflurane ~0.2%; cross-reactivity is vanishingly rare. Sevoflurane is metabolized to HFIP, never forms TFA intermediates, and cannot cause TFA-mediated hepatitis.

Malignant Hyperthermia (MH) Crisis Management

Malignant Hyperthermia is a life-threatening, pharmacogenetic autosomal dominant skeletal muscle channelopathy primarily caused by mutations in the ryanodine receptor 1 gene ( RYR1 , chromosome 19q13.1) (~70-80% of cases) or the CACNA1S gene (voltage-gated dihydropyridine calcium channel). MH Pathophysiology: Trigger (All Volatiles, Succinylcholine)

  • |
  • v
  • Mutated RYR1 Calcium Channel in Sarcoplasmic Reticulum
  • |
  • v
  • Uncontrolled Calcium Efflux into Skeletal Myoplasm
  • |
  • v
  • Massive Actin-Myosin Cross-Bridging & Aerobic Hypermetabolism
  • |
  • +-------------------+-------------------+
  • | |
  • Rapid CO2 Production, Rigidity Lactic Acidosis, Temperature Spike (>42°C)
  • Hyperkalemia, Arrhythmias Rhabdomyolysis, Renal Failure

Triggers: ALL volatile inhalational anaesthetics (sevoflurane, desflurane, isoflurane, halothane) and the depolarizing muscle relaxant succinylcholine . Nitrous oxide, xenon, and all intravenous agents (propofol, opioids, ketamine, non-depolarizing relaxants) are safe non-triggers.

Pathophysiology: Exposure to a trigger precipitates sustained, uncontrolled calcium release from the sarcoplasmic reticulum into the myoplasm. Intracellular calcium pumps and actomyosin ATPases work at maximal capacity, generating an extreme hypermetabolic crisis.

Clinical Signs:

Earliest and most sensitive indicator: Unexplained, precipitous rise in end-tidal CO 2 \text{CO}_2 CO 2 ​ ( E T C O 2 ETCO_2 ETC O 2 ​ ) refractory to progressive increases in minute ventilation.

Tachycardia, tachypnea, skin mottling, cyanosis.

Masseter muscle spasm (MMR) or generalized "board-like" skeletal muscle rigidity.

Hyperthermia: A late confirmation sign; core temperature can rise rapidly by 1 − 2 ∘ C 1-2^\circ\text{C} 1 − 2 ∘ C every 5 minutes , reaching > 42 − 43 ∘ C >42-43^\circ\text{C} > 42 − 4 3 ∘ C .

Mixed severe respiratory and metabolic lactic acidosis, hyperkalemia (fatal arrhythmias), and rhabdomyolysis with dark tea-colored myoglobinuria.

Immediate Crisis Protocol:

Cease Triggers: Immediately discontinue volatile agents and succinylcholine. Inform the surgical team to halt surgery immediately.

Hyperventilate: Administer 100% O 2 \text{O}_2 O 2 ​ at high flows ( > 10 L/min >10\text{ L/min} > 10 L/min ) with a minute ventilation 2-3 times baseline. Attach activated charcoal filters to inspiratory and expiratory limbs of the circuit without delaying resuscitation.

Administer Dantrolene: Give Dantrolene sodium 2.5 mg/kg IV bolus immediately . Repeat boluses of 1.0-2.5 mg/kg every 5-10 minutes until hypercapnia, tachycardia, and rigidity resolve (cumulative doses up to 10 mg/kg or more). Dantrolene binds directly to the RYR1 receptor, halting intracellular calcium efflux.

Active Cooling: Infuse cold normal saline ( 4 ∘ C 4^\circ\text{C} 4 ∘ C ), apply ice packs to axillae, groin, and neck, and initiate cold gastric/bladder lavage. Stop cooling when core temperature falls below 38.5 ∘ C 38.5^\circ\text{C} 38. 5 ∘ C to prevent hypothermic rebound.

Treat Hyperkalemia: Administer calcium chloride (10 mg/kg), regular insulin (10 units) with 50 mL 50% dextrose, and sodium bicarbonate (1-2 mmol/kg).

Renal Protection: Maintain urine output > 2 mL/kg/h >2\text{ mL/kg/h} > 2 mL/kg/h with intravenous fluids, mannitol, or furosemide to prevent myoglobin cast nephropathy.